If they value the market for 2591 in contrast with Daybue for Retts, at 5 times on the low end and up to 10 times on the high end, then the current SP should not really worry us, especially when Jon has said DCF model would be used to value to the company.
If you equate the value (in rough terms) for Skyclaris and Retts and what Biogen paid, then we could be in for a healthy ROI.
Neuren Media and Analyst Coverage, page-1278
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.79 |
Change
0.180(1.32%) |
Mkt cap ! $1.784B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $3.107M | 224.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 9345 | $14.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.83 | 1394 | 1 |
View Market Depth
| Last trade - 15.59pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |